PODD241220P440000
- 0.00
- 0.000.00%
Insulet Newsroom
United States Diabetes Device Market Forecast Report and Company Analysis 2024-2032 Featuring BD, Roche, Medtronic, Insulet, Abbott, Dexcom, Tandem Diabetes Care, Ypsomed Novo Nordisk, Eli Lilly - ResearchAndMarkets.com
Here's Why Insulet (PODD) Is a Strong Growth Stock
Does Insulet (NASDAQ:PODD) Deserve A Spot On Your Watchlist?
Peering Into Insulet's Recent Short Interest
Are Wall Street Analysts Predicting Insulet Stock Will Climb or Sink?
If You Invested $1000 in Insulet a Decade Ago, This Is How Much It'd Be Worth Now
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Express News | Insulet Corp : Leerink Partners Raises Target Price to $290 From $278
PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
Insulet Adds Abbott's FreeStyle Libre 2 Plus to Omnipod 5's Compatibility Roster
CCORF Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $269
Insulet's Strategic Advancements and Market Positioning Drive Buy Rating
Citi Research's 'SMID Value' Rec List – CHWY, FHN, PODD, and More
Insulet To Present At Wolfe Research Healthcare Conference; Webcast At 12:00 PM ET
Insulet Announces Omnipod 5 System Is Now Compatible With Abbott's FreeStyle Libre 2 Plus Sensor In The U.S.
Express News | Insulet Announces Omnipod® 5 System Is Now Compatible With Abbott’s Freestyle Libre 2 Plus Sensor in the U.S.
Baptista Downgrades Insulet to Underperform
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Impressive Earnings May Not Tell The Whole Story For Insulet (NASDAQ:PODD)
Insulet's (NASDAQ:PODD) Solid Profits Have Weak Fundamentals